Deuterium-Enriched Neuroactive Steroids for GABA Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current neuroactive steroids for treating CNS-related disorders have limitations in modulating brain excitability and addressing various neurological conditions, with a need for more potent and specific agents that can interact with the GABA receptor complex effectively.
Innovation Solution
Development of deuterium-enriched neuroactive steroids that act as GABA modulators, designed to enhance the therapeutic effects on mood disorders, anxiety, seizures, and other CNS-related conditions by interacting with the GABA A receptor, offering potential as therapeutic agents for conditions such as post-partum depression, anxiety, epilepsy, and tremors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional neuroactive steroids are used to treat CNS disorders, then basic GABA modulation is achieved, but potency and therapeutic effectiveness are limited
Solution Approach 1:
The patent applies parameter changes by substituting hydrogen atoms with deuterium atoms in the steroid molecule structure. This isotopic substitution changes the physical and chemical parameters of the compound, resulting in enhanced metabolic stability and prolonged duration of action at the GABA receptor complex, thereby improving therapeutic effectiveness for CNS disorders
Solution Approach 2:
The patent creates composite molecular structures by combining the steroid core framework with deuterium-enriched functional groups. This composite approach integrates the neuroactive properties of steroids with the metabolic stability benefits of deuterium labeling, producing compounds with superior therapeutic profiles for treating anxiety, depression, and seizure disorders
2Speed
If existing GABA modulators are administered to achieve therapeutic effects, then CNS disorder treatment is provided, but rapid onset of action is not achieved
Solution Approach 1:
The deuterium substitution changes the kinetic parameters of metabolic degradation, slowing down enzyme-catalyzed breakdown of the neuroactive steroid. This parameter modification allows the compound to maintain therapeutic concentrations more effectively, contributing to both rapid onset and consistent therapeutic action
3Adaptability or versatility
If standard neuroactive steroids are used to modulate brain excitability, then basic therapeutic coverage is provided, but specificity for particular CNS conditions is insufficient
Solution Approach 1:
The deuterium enrichment changes the metabolic parameter of the steroid, extending its half-life and duration of action. This allows for more condition-specific therapeutic coverage with optimized dosing regimens, improving adaptability across different CNS disorders while potentially reducing the total quantity of substance required
Solution Approach 2:
The patent applies local quality by selectively deuterating specific positions on the steroid molecule where metabolic oxidation typically occurs. This localized modification enhances metabolic stability at critical sites while preserving the overall neuroactive properties, enabling better specificity for particular CNS conditions
Data Source
AI summary
Described herein are deuterium-enriched neuroactive steroids of the Formula (II) or a pharmaceutically acceptable salt thereof; wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, Rlla, Rllb, R12a, R12b, R16a, R16b, R17, R19, Ra, and Rb and subvariables thereof are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment.